We investigated the variability of N-terminal probrain natriuretic peptide (NT-proBNP) and its relation to known confounding variables in patients with stable chronic heart failure who were on a stable optimized medication regimen.
Serial measurement of natriuretic peptides in heart failure patients has been suggested to have utility both for the guidance of management strategies (1) (2) (3) (4) (5) and for improved prognostication (6, 7 ) . This application, however, relies on knowledge about the corresponding biological variation at the respective follow-up interval chosen. To date, such intermediate-term variations are largely unknown because studies assessing biological variability in heart failure patients have either examined short-term (week-to-week) variations (8) (9) (10) (11) or long-term (year-to-year) variations (12, 13 ) . Because patients in the outpatient setting are rarely seen on a weekly or a yearly basis, this gap in knowledge of intermediate-term variability must be addressed.
Results of prior studies suggest that short-term variability of natriuretic peptides is high (8) (9) (10) (11) and reference change values (RCVs) 5 -the percentage of change of hormonal level considered to be of possible diagnostic or prognostic importance-have been found to exceed 100% of the initial value (11 ) . These high values are controversial (12 ) because they appear to be related to the skewed distribution of measured hormonal values and improve after normalizing transformation of the data (13 ) . Furthermore, the biological variation of brain natriuretic peptide (BNP) appears to be greater than that of N-terminal pro-BNP (NTproBNP) (14 ) .
Of those studies in which very large within-person variations were observed, only 2 (9, 11 ) have included patients with heart failure. Investigation of natriuretic peptide variations in heart failure patients is important because patients with heart failure have much higher baseline hormonal values and when these patients are clinically stable, their within-person variability expressed in terms of CV would be expected to be substantially lower than that of healthy individuals. In patients undergoing treatment for heart failure, stability of medication and adherence to guidelines are important aspects to consider because, for example, administration of ␤-blockers could significantly influence BNP levels (15 ) . Furthermore, stability of clinical state-the prerequisite for determination of biovariability-might be difficult to ascertain in heart failure patients, especially with longer intervals between tests.
Because adherence to guidelines has been incomplete in previous studies and stability of chronic heart failure has not always been confirmed by direct assessment, we prospectively investigated in an outpatient setting the intermediate-term variability of NTproBNP in patients with stable chronic heart failure who were undergoing treatment with individually optimized stable medication regimens.
Materials and Methods
This study constitutes the NT-proBNP arm of a multimarker project on neurohumoral pathways in chronic heart failure. The local ethics committee approved the project, which conforms to the principles of the declaration of Helsinki. Patients were recruited prospectively and continuously from the heart failure outpatient clinic of the University Hospital Heidelberg, Germany. Between September 2006 and June 2007, all patients being seen in follow-up visits to the clinic (n ϭ 766 patients) were screened for eligibility. A total of 90 patients fulfilled the criteria for inclusion in the study described below. Of these, 43 patients consented to the study protocol.
Two patients withdrew their consent after the first visit. Therefore, the final study population consisted of 41 patients. At 3-month-follow-up, 3 patients showed significant unexplained weight loss compared to 1-month follow-up. In accordance with the study protocol, they remained in the data set for 1-month follow-up because they were stable in all other parameters up to that time, but were excluded from further analysis at 2-month and 3-month follow-up, although they were stable according to all other criteria, including self-perceived clinical status. Therefore, at 3-month-follow-up the final study populations consisted of 38 patients.
The diagnosis of heart failure was established according to published guidelines (16 ) , and the etiology was confirmed by results of cardiac catheterization, which was performed in all patients during first contact with our clinic. Patients were eligible if they met all of the following criteria: (a) chronic heart failure known for at least 1 year followed at our clinic; (b) stable clinical condition with no hospitalization attributable to worsening heart failure within the previous 6 months; (c) New York Heart Association (NYHA) functional class I-III; (d) subjectively stable clinical condition since the last visit to the outpatient clinic, as judged both by the patient and the physician; (e) ischemic or idiopathic dilated cardiomyopathy as the etiology of heart failure; (f) in case of ischemic origin, no revascularization performed within the previous 6 months and no revascularization planned during the next 6 months; (g) age Ͼ18 years; (h) complete adherence to guidelines of medical treatment regarding class of drugs; (i) individually optimized doses of guidelinerecommended drugs for at least 4 weeks before study inclusion; (j) no recent involuntary change of weight exceeding 2 kg within 4 weeks before inclusion; and (k) serum sodium levels within reference intervals, indicating euvolemic state.
Patients were excluded if they met 1 or more of the following criteria: (a) pregnancy, (b) significant renal dysfunction as identified by a creatinine concentration Ͼ176.8 mol/L (2 mg/dL), (c) unstable renal function as identified by a change in creatinine Ͼ20% since the last visit, (d) thyroid dysfunction, (e) history of pulmonary disease, (f) valvular heart disease, (g) inability to cooperate or to comprehend the study protocol, (h) active listing for cardiac transplantation, (i) primary pulmonary hypertension, (j) in cases of ischemic origin: angina, angina-equivalent, or ischemia-induced changes in the electrocardiogram during bicycle exercise testing of at least 7 MET (metabolic equivalent test).
Blood samples for NT-proBNP analysis were taken from an indwelling venous catheter after patients had rested for a period of 30 min. The time of sample collection was between 2 and 4 PM, because NTproBNP has been demonstrated to be stable during the afternoon (9 ) . After the initial visit (T0), patients were seen again after 2 weeks and 4 weeks (T1 and T2) and again after 12 weeks (T 3 ). For T1 and T2, a delay of 2 days was allowed, and for T 3 , a delay of 4 days. EDTA Vacutainer tubes were used, and samples were centrifuged at 4°C immediately after collection to separate the plasma, which was frozen at Ϫ20°C.
NT-proBNP was measured by use of a fully automated Elecsys® Roche Diagnostics 2010 analyzer. Assay precision, analytical sensitivity, interferences, and stability for this method have been previously described (17, 18 ) . To minimize the analytical variance, all samples were analyzed together in 1 run. We determined within-run imprecision by using samples from our study patients and synthetic controls. The CVs for analysis of 21 aliquots of each sample-again, all sam-ples within 1 assay run-were 1.6% (sample mean, 137 ng/L), 1.8% (sample mean, 150 ng/L), 1.0% (sample mean, 581 ng/L), 1.2% (sample mean, 1222 ng/L), and 1.5% (sample mean, 5239 ng/L), giving a total variation of 1.4%. NT-proBNP results are presented in nanograms per liter. To convert to picomoles per liter, multiply results by 0.118.
NT-proBNP was considered as a continuous variable for all calculations. Renal function was assessed both by serum creatinine concentrations and glomerular filtration rate (GFR) as estimated by the simplified Modification of Diet in Renal Disease (MDRD) formula (19, 20 ) .
The total CV (CV t ) and the analytical CV (CV a ) provided the basis for calculating the individual biological CV (CV i ) where CV i ϭ (CV t 2 -CV a 2 ) [1/2] . The CV was calculated as CV ϭ 100 ϫ (SD/mean). RCVs were calculated from median CV t values, according to the formula:
/n s ) [1/2] , where Z ϭ 1.96 (i.e., the Z-score for 95% confidence with a 2-tailed P Ͻ 0.05); n a is the number of replicate assays; and n s is the number of patient samples to estimate each of the 2 homeostatic set points. The index of individuality (IOI) was calculated as:
/CV G (ϭ intraindividual varianceϩanalytical variance/interindividual variance) (21, 22 ) . Here, a low IOI (Ͻ0.48) is considered to reflect strong individuality, which in turn indicates that an individual patient should be assessed with respect to his or her individual hormonal level. In contrast, a high IOI (Ͼ1. 4) indicates that this patient should be assessed with respect to population-derived reference intervals (21 ) . Continuous data were tested by use of the 2-sample Wilcoxon test, Kruskal-Wallis-test, and 1-way ANOVA, as appropriate. Univariable and multivariable linear regressions were performed by using uncorrected or log-transformed values for the dependent variable, as appropriate, and the Spearman method was used to assess correlations between variables. The relation between relative change and hormonal level was assessed according to the method proposed by Bland and Altman (23, 24 ) . An arbitrary level of 5% statistical significance (P Ͻ 0.05; 2-tailed) was assumed throughout. Calculations were performed with SAS version 9.1.
Results
Our patients represent the average population at a tertiary reference center. Dilated cardiomyopathy was the predominant clinical presentation in this population, which included 80% men with a mean age of 61 years. The majority of patients fell into NYHA functional classes I and II. For complete characteristics see Table  1 . At all 4 sampling intervals, patients were stable with regard to weight (P ϭ 0.99), waist circumference (P ϭ 0.94), renal function (P ϭ 0.94 for creatinine; P ϭ 0.90 for MDRD-estimated GFR), serum sodium concentration (P ϭ 0.71), blood pressure (P ϭ 0.82 for systolic; P ϭ 0.17 for diastolic), heart rate (P ϭ 0.47), and NTproBNP (P ϭ 0.99). No changes in medication or NYHA functional class occurred. For a complete data profile according to sample interval, see Table 2 .
In this population of stable heart failure patients, NT-proBNP showed biological variability of 11.3% to 18.9% depending on the time interval between tests. Corresponding RCVs were between 31.4% and 52.5%. The indices of individuality ranged from 0.07-0.12. More detailed results are available in Table 3 . CVs for the 4 test intervals showed a variable pattern of intercorrelation. Whereas 2-month coefficients did not correlate with other coefficients (r ϭ 0.17, P ϭ 0.28 vs 14-day; r ϭ 0.21, P ϭ 0.20 vs 1-month; r ϭ 0.22; P ϭ 0.17 vs 3-month), all other coefficients were found to be intercorrelated: 14-day coefficients correlated with 1-month (r ϭ 0.66, P Ͻ 0.001) and 3-month (r ϭ 0.45, P Ͻ 0.01) coefficients and 1-month coefficients corre- lated with 3-month coefficients (r ϭ 0.33, P Ͻ 0.05). We did not find any correlation between relative interval change in NT-proBNP and the corresponding interval changes in weight or waist circumference, renal function (as indicated by either serum creatinine or MDRD-estimated GFR), or heart rate at any of the 4 sampling intervals (data not shown). For hemoglobin, only the relative interval change at 3-month follow-up correlated with relative interval change in NT-proBNP (r ϭ 0.49, P Ͻ 0.01), with no correlation found at the other sampling intervals. Regression analyses did not reveal any significant influence of baseline NT-proBNP concentrations on the corresponding change values (P ϭ 0.38, P ϭ 0.69, P ϭ 0.18, and P ϭ 0.48 for 14-day, 1-month, 2-month, and 3-month values, respectively). Consequently, no further subdivision according to NT-proBNP grouping was performed. The corresponding graphs can be seen in Fig. 1 . Likewise, NYHA functional class, sex, age, weight or waist circumference, heart rate, hemoglobin levels, and ejection fraction were not found to significantly influence the different change values (data not shown). Renal function, as indicated by either serum creatinine or MDRD-estimated GFR, was found to have a small but significant relationship with 14-day change values (␤-coefficient, Ϫ0.18; SE, 0.08; intercept, 0.42; SE, 0.1; r 2 , 0.12; residual SD, 0.13; P ϭ 0.03 for creatinine; ␤-coefficient, 0.003; SE, 0.001; intercept, 0.02; SE, 0.09; r 2 , 0.12; residual SD, 0.13; P ϭ 0.04 for MDRD-estimated GFR) with no significant relationship with the other change values (P ϭ 0.29, P ϭ 0.60, and P ϭ 0.14 for 1-month, 2-month, and 3-month values of MDRD-estimated GFR, respectively).
Discussion
We determined the intermediate-term biological variation of NT-proBNP in stable chronic heart failure and its relation to change in known confounding variables. Importantly, we did so in an outpatient setting in patients who were on individually optimized stable medication regimens. We found that patients with stable chronic heart failure and on stable medication had NTproBNP biological variation of 11% to 20% with sampling periods ranging from 14 days to 3 months. We also found that the corresponding indices of individuality for these sampling periods ranged from 0.07-0.15 and indicated high individuality of values. Lastly, the individual biological variability of NT-proBNP does not appear to be influenced by known confounders for NT-proBNP itself, such as NYHA functional class, sex, age, weight or waist circumference, hemoglobin levels, ejection fraction, or renal function.
We chose to investigate NT-proBNP because it is more stable than BNP and its variation appears to be lower (14 ) . Also, to the best of our knowledge, this is the first study to address biovariability of natriuretic peptides during intermediate follow-up intervals and only the second study to address indices of individuality in chronic heart failure. In patients the confounding effects of clinical stability and titration of drugs must be controlled to assess true biological variability. In this context it is interesting to note that only approximately one-ninth of patients attending our clinic were eligible -or inversely, about 90% of patients in an outpatient setting presented some degree of clinical instability.
Previous reported studies on short-or long-term variability found RCVs around 100% (8, 9 ) (11 ), others found CVs between 20% and 30% (10, 12, 13, 25, 26 ) . The key to understanding these results is the rigidity of the definition of stability of heart failure. In studies that expended large efforts to ascertain stability (12, 25, 26 ) the CVs found were lower than in studies with less strict criteria (9, 11 ) . Consequently, we found The dotted lines indicate 1.96 ϫ SD of the mean of the differences (95% confidence with P Ͻ 0.05).
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CVs for NT-proBNP to be around 20%. Our study is a valuable extension to current knowledge because intermediate-term variation must be quantified to aid interpretation of trials targeting guidance of medical therapy or routine application as they relate to normal follow-up duration in outpatient settings.
Important points must be considered with regard to estimation of CVs for NT-proBNP. The skewed distribution of NT-proBNP values can be converted by log-transformation to a normal distribution (12, 25 ) , a process that results in lower CVs and eliminates the problem of a paradoxical decrease Ͼ100%. It must be emphasized, however, that CVs derived by this approach would apply only to log-transformed values, thus limiting clinical applicability. After retransformation as suggested by Fokkema et al. (27 ) , the CV borders are comparable to those derived by use of nontransformed values. In addition, the CV of logtransformed values is not independent of the scale of the values, necessitating strict adherence to scale. A more important consideration is that the concept of biological variation around a homeostatic set-point might not hold for . This could be the case because CVs for natriuretic peptides do not represent random variation, but rather the close balance between hemodynamics and neuroendocrine regulation vs counterregulation (28 ) ; pulsatile secretion of BNP (and consequently NT-proBNP) has already been demonstrated in healthy individuals (29 ) .
The interpretation of IOI has been reported previously (21 ) and is detailed above. So far, only 1 reported study (25 ) has included data on IOI in heart failure patients. As in the present study for intermediate follow-up, the earlier study demonstrated that IOIs of week-to-week variations were relatively low, paralleling our findings indicating that NT-proBNP shows high interindividual variation with relative stability of values for the individual patient. This relative stability of NT-proBNP in the individual patient compared to between-patient variability further strengthens the notion raised above that NT-proBNP might not vary randomly and could be an explanation for the difference between high CVs observed in stable patients vs small differences in serial NT-proBNP concentrations when these indices are successfully used in therapy-guiding trials (1, 2 ) . Recently it has been suggested that the additional prognostic value of serial evaluation might be more related to a categorical change with respect to a cutoff concentration (6, 7 ) than to the use of relative or absolute changes in concentration.
Despite the widespread use of natriuretic peptides, there is a paucity of data on possible confounders for serial measurements in patients with stable heart failure. We confirmed the only 2 available studies regarding the absence of influence of age, sex, and renal function on short-term (25 ) and long-term (13 ) variations of NT-proBNP and have extended these findings to important confounders such as NYHA functional categories and obesity as represented by weight and waist circumference. More importantly, we did not find any relationship between change of NT-proBNP and changes in renal function (either for serum creatinine or MDRD-estimated GFR) or body weight (as indicated by weight or waist circumference) at any of the 4 sampling intervals. Only medium-term, but not shortterm, changes in hemoglobin were found to be related to changes in NT-proBNP. Because hemoglobin influences NT-proBNP concentrations, it is possible that the short-term changes in hemoglobin measured here reflect biovariability or smaller changes in fluid intake that would not exert sizeable influence on NT-proBNP levels, whereas medium-term changes in hemoglobin might be a reflection of more slowly developing patterns (e.g., evolving anemia), which could influence NT-proBNP. These findings are important in clinical practice, in which change of NT-proBNP will be interpreted in light of other variables. Furthermore, such findings again provide indirect support for the notion that NT-proBNP does not vary randomly.
Our study has several limitations. The relatively small number of patients included may hinder adequate statistical analysis, but the size of our study population is comparable to previous, related studies. In addition, the numerous and strict selection criteria should give this study even greater value, although these criteria might also adversely impact on clinical variables and patient selection, effectively reducing the number of individuals included in the study and possibly the clinical transferability of the findings. We think that RCVs should be established only in clinically stable patients to allow later application to more unstable settings. Loss of individuals from the study due to patients dropping out could have introduced possible bias to the study. We cannot completely rule out the presence of hidden hemodynamic changes; it is possible that undetected intermittent changes of rhythm contributed to the large variability seen in some patients and might explain some of the discrepancy between obvious clinical stability and large changes in measured marker values. Because we did not perform invasive testing or long-term Holter follow-up, we can only speculate about this possibility. Consequently, despite the rigorous definition of stability used in our study, it is still possible that we did not measure pure biological variability but that to a certain extent clinically undetected variations in phenotype may have been included in our determinations.
In conclusion, despite previous reports of values around 80%, variation of NT-proBNP at 14-day, 1-month, 2-month, and 3-month follow-up is lower in a prespecified population of patients with stable heart failure and is not related to changes in renal function or weight. In view of the low index of individuality we observed, within-person variation is quite low compared to between-person variation. Consideration of these facts is important for the interpretation of trials and the use of NT-proBNP in monitoring patients with heart failure.
